Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Non Operating Income (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Non Operating Income for 13 consecutive years, with -$49717.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 2100.68% year-over-year to -$49717.0, compared with a TTM value of -$71624.0 through Nov 2025, down 422.81%, and an annual FY2021 reading of -$594270.0, up 86.57% over the prior year.
  • Non Operating Income was -$49717.0 for Q4 2025 at CNBX Pharmaceuticals, down from -$19347.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $111142.0 in Q3 2021 and bottomed at -$647523.0 in Q2 2021.
  • Average Non Operating Income over 5 years is -$86911.4, with a median of -$8751.0 recorded in 2022.
  • Peak annual rise in Non Operating Income hit 282.16% in 2021, while the deepest fall reached 4383.38% in 2021.
  • Year by year, Non Operating Income stood at -$212670.0 in 2021, then surged by 94.88% to -$10879.0 in 2022, then soared by 39.12% to -$6623.0 in 2023, then skyrocketed by 137.52% to $2485.0 in 2024, then plummeted by 2100.68% to -$49717.0 in 2025.
  • Business Quant data shows Non Operating Income for CNBX at -$49717.0 in Q4 2025, -$19347.0 in Q2 2025, and -$5045.0 in Q1 2025.